

A proposal on how to authorise PPPs, reduce risks, learn and adapt

Workshop on pesticide fate in soil and water
in the northern zone

9 September 2016

Henrik Sundberg, Sofia Bejgarn, Mats
Allmyr, Johan Axelman


3 legs in concert



From the beginning



Perspective: predicting adverse effects



Perspective: knowledge

- Our knowledge on environmental fate and behaviour of PPPs is greater than ever before
- Complexity of risk assessments increases
- Shouldn't our evaluations become smaller rather than larger when knowledge increase?
- Shouldn't the outcome of the authorisation process of PPPs with similar properties be similar?

Perspective: how precise are risk estimates vs how precise are variables

- DT50-values from 4 soils
- Weather data
- Application window
- How shall we relate to the model output?
- Why isn't EU evaluations of a.s. enough?

Our roles?

- EU-approval
 - Remove the worst a.s.
 - Agree on endpoints
- National authorisation
 - Reduce risks


Perspective: expectations on the competent authority

- Authorise PPPs which don't risk causing unacceptable effects
- Not hamper market access for PPPs fulfilling stipulated criteria


Perspective: risk assessments vs administration

- Is complex RA the only reason why we don't keep the stipulated time frames?
 - Data protection?
 - Complex authorisation process


Calibrate tier 1 AF



Decrease the current level of protection



Increase the current level of protection



Strategic risk mitigation

- Run-off reduction
 - How big is the problem with run-off?
 - Mitigation towards all adjacent waters?
 - Is run-off a PPP- or crop-specific problem?
 - Mitigation in fields when run-off is possible?
- Dams/meanders
 - Increase degradation?
 - Mitigation for drainage?
- Education
- Optimise use


Retrospective RA

- Do PPP-use result in environmental effects (both biological and chemical)?
- Can environmental effects be reduced by strategic mitigation measures?
- How much do PPPs contribute to effects (what is the attributable fraction of PPPs)?

Are these models sufficient for national authorisations of PPPs?

- PEC_{SW} :
 1. FOCUS step1
- PEC_{GW} :
 1. Agree on one NZ-scenario
 2. Validate from PLAP + additional MS-specific fields
- Models for targeted screening/monitoring?

3 legs in concert



Thank you!